Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-year extension study of deferasirox 10 mg/kg/day in pediatric patients with transfusion-dependent β-thalassemia major
2015-003535-35Phase 2
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in beta thalassemia major, sponsored by Novartis. Primary endpoint: Participants with adverse events by primary System Organ Class (SOC).
02
Drugs
deferasirox
03
Conditions
beta thalassemia major
Beyond the preview
Go deeper on 2015-003535-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003535-35.